Considering that Infuse Bone Graft has been the subject of numerous studies and investigations that have called its safety into question, it’s not at all surprising that Medtronic’s spine revenue declined.
New York, New York (PRWEB) November 20, 2012
The ongoing controversy surrounding Medtronic Infuse Bone Graft continues to weigh on the company’s bottom line, Bernstein Liebhard LLP reports. According to Medtronic Inc.’s third quarter earnings statement, revenue from its Spine business declined 5 percent on a constant currency basis or 7 percent as reported, while Core Spine revenue declined 2 percent on a constant currency basis. Revenue from bone morphogenetic protein (BMP) products, which include Infuse, declined 19 percent on a constant currency basis.*
“Considering that Infuse Bone Graft has been the subject of numerous studies and investigations that have called its safety into question, it’s not at all surprising that Medtronic’s spine revenue declined,” says Bernstein Liebhard LLP, a nationwide law firm currently evaluating lawsuits on behalf of individuals who may have suffered alleged Infuse Bone Graft injuries, including respiratory problems, nerve damage, and wrongful death.
Medtronic Infuse Bone Graft Lawsuits
Medtronic Infuse Bone Graft was approved by the U.S. Food & Drug Administration (FDA) in 2002 for stimulating spinal bone growth in patients with a degenerative disease affecting the lower spine. In 2008, the FDA warned that Infuse Bone Graft had been associated with serious complications when used off-label in cervical spine fusions, including excessive swelling in the neck, compressed airways, difficulty breathing, problems swallowing and nerve damage**
In 2011, The Spine Journal dedicated an entire issue to studying the risks of the recombinant bone morphogenetic protein-2, or BMP-2, used in Medtronic Infuse Bone Graft. The journal’s investigation found that 13 Medtronic-funded studies downplayed or entirely omitted evidence of safety issues with Infuse. *** Most recently, a U.S. Senate Finance Committee raised disturbing questions about the integrity of the research used to gain FDA approval of Infuse. In a report released last month, Senate investigators charged that Medtronic deliberately manipulated studies to downplay Infuse Bone Graft side effects and promote off-label use of the bone protein. The report also found that Medtronic paid out $210 million in royalties, consulting fees, and other payments to the doctors who co-authored the Medtronic-sponsored Infuse studies.****
Bernstein Liebhard LLP is offering free lawsuit consultations to anyone allegedly injured by Medtronic Infuse Bone Graft. Victims of serious Medtronic Infuse complications may be entitled to compensation for their medical care, pain and suffering, and other damages. A wealth of information regarding the potential dangers associated with Medtronic Infuse Bone Graft is available on Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. For more information about Medtronic Infuse Bone Graft lawsuits, please contact one of our attorneys by calling 877-779-1414.
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP